Manufacturer of Controlled Substances; Notice of Registration, 28074-28075 [E7-9639]
Download as PDF
<![CDATA[
28074
Federal Register / Vol. 72, No. 96 / Friday, May 18, 2007 / Notices
Dated: May 10, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9606 Filed 5–17–07; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
By Notice dated November 2, 2006,
and published in the Federal Register
on November 8, 2006, (71 FR 65544),
Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
pwalker on PROD1PC71 with NOTICES
By Notice dated December 14, 2006,
and published in the Federal Register
on December 22, 2006, (71 FR 77065–
77066), Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of 14–
Hydroxymorphinone (9654), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substances in bulk
as an intermediate for use in the
production of another controlled
substance.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated Johnson
Matthey Inc to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9617 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
17:06 May 17, 2007
Jkt 211001
Drug
Schedule
Nabilone (7379) ............................
Noroxymorphone (9668) ..............
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sales to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Johnson Matthey Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9629 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 14, 2006,
and published in the Federal Register
on December 22, 2006, (71 FR 77065),
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Remifentanil (9739), a
basic class of controlled substance listed
in schedule II.
The company plans on producing this
item for sale to its customers, who are
final dosage manufacturers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated Johnson
Matthey Inc to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: May 9, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9634 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 14, 2006,
and published in the Federal Register
on December 22, 2006, (71 FR 77065–
77066), Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of 14–
Hydroxymorphinone (9654), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substances in bulk
as an intermediate for use in the
production of another controlled
substance.
E:\FR\FM\18MYN1.SGM
18MYN1
28075
Federal Register / Vol. 72, No. 96 / Friday, May 18, 2007 / Notices
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc. to manufacture
the listed basic class of controlled
substance is consistent with the public
interest at this time. DEA has
investigated Johnson Matthey Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: May 9, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9639 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated January 23, 2007, and
published in the Federal Register on
January 30, 2007, (72 FR 4298),
Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I and II:
pwalker on PROD1PC71 with NOTICES
Drug
Schedule
Codeine-N-oxide (9053) ...............
Difenoxin (9168) ...........................
Dihydromorphine (9145) ...............
Morphine-N-oxide (9307) .............
Norlevorphanol (9634) ..................
Normorphine (9313) .....................
Tetrahydrocannabinols (7370) .....
Nabilone (7379) ............................
Alfentanil(9737) ............................
Amphetamine (1100) ....................
Ecgonine (9180) ...........................
Codeine (9050) .............................
Dextropropoxyphene, bulk(9273)
Dihydrocodeine (9120) .................
Diphenoxylate (9170) ...................
Diprenorphine (9058) ...................
Etorphine HCL (9059) ..................
Fentanyl(9801) .............................
Hydrocodone (9193) .....................
VerDate Aug<31>2005
17:06 May 17, 2007
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 211001
Drug
Schedule
Hydromorphone (9150) ................
Levo-alphacetylmethadol (9648) ..
Levorphanol(9220) .......................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Metopon (9260) ............................
Morphine (9300) ...........................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, granulated (9640) ............
Opium, powdered (9639) .............
Oxycodone (9143) ........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Phenazocine (9715) .....................
Alfentanil(9737) ............................
Remifentanil (9739) ......................
Sufentanil(9740) ...........................
Thebaine (9333) ...........................
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The firm plans to manufacture the
listed controlled substances for internal
use and for sale to other companies.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Mallinckrodt Inc. to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated
Mallinckrodt Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9619 Filed 5–17–07; 8:45 am]
Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule II:
Drug
Phenylacetone (8501) ..................
Coca Leaves (9040) .....................
Opium, raw (9600) .......................
Poppy Straw (9650) .....................
Poppy Straw Concentrate (9670)
Schedule
II
II
II
II
II
The company plans to import the
listed controlled substances for the
manufacture of controlled substances in
bulk for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Mallinckrodt Inc. to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Mallinckrodt Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–9635 Filed 5–17–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Registration
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated February 5, 2007 and
published in the Federal Register on
February 12, 2007, (72 FR 6579),
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
By Notice dated August 15, 2006, and
published in the Federal Register on
August 22, 2006, (71 FR 48947),
Noramco Inc., Division of OrthoMcNeil, Inc., 500 Old Swedes Landing
Road, Wilmington, Delaware 19801,
made application by renewal, and by
separate correspondence dated June 2,
E:\FR\FM\18MYN1.SGM
18MYN1
]]>Agencies
[Federal Register Volume 72, Number 96 (Friday, May 18, 2007)]
[Notices]
[Pages 28074-28075]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-9639]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated December 14, 2006, and published in the Federal
Register on December 22, 2006, (71 FR 77065-77066), Johnson Matthey
Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West
Deptford, New Jersey 08066, made application by letter to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of 14-Hydroxymorphinone (9654), a basic class of
controlled substance listed in schedule II.
The company plans to manufacture the listed controlled substances
in bulk as an intermediate for use in the production of another
controlled substance.
[[Page 28075]]
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Johnson Matthey Inc. to manufacture the listed basic class of
controlled substance is consistent with the public interest at this
time. DEA has investigated Johnson Matthey Inc. to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with State and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic class of controlled substance listed.
Dated: May 9, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-9639 Filed 5-17-07; 8:45 am]
BILLING CODE 4410-09-P
